Abstract
The effectiveness of new personalized treatment procedures in oncology is based on the fact that certain tumors exhibit specific molecular features.
More in detail, neoplastic tissues of patients should display a specific biomarker, most often a specific genetic alteration and/or under/overexpression of a definite protein, that could be the target of its respective drug. Immunohistochemical and molecular analyses, which usually include examination of nucleic acids from either tissues or fluids, are common tests to define the status of a tumor.
This review focuses on the pathologist’s role in carefully controlling pre- analytic procedures and standard operating procedures that are a crucial prerequisite to reach reliable and reproducible results. Six paradigmatic applications of targeted therapy, for which pathological diagnosis plays a fundamental role, are summarized. Traditional and next-generation sequencing are also addressed from the pathologist's perspective as well as the importance pathologists have in this shift to more accurate definition of disease risk and prognostication of therapy response in the personalized medicine era.
Keywords: Target therapy, biomarker, pathologist's perspective, Immunohistochemistry, FFPE tissue, molecular analyses, traditional sequencing, next-generation sequencing.
Current Cancer Drug Targets
Title:Cancer Targeted Therapy Strategy: The Pathologist’s Perspectives
Volume: 18 Issue: 5
Author(s): Lara Alessandrini, Tiziana Perin, Shahin Kadare, Lino del Pup, Lorenzo Memeo, Agostino Steffan, Lorenzo Colarossi, Massimiliano Berretta, Paolo De Paoli and Vincenzo Canzonieri*
Affiliation:
- Divisions of Pathology, CRO IRCCS National Cancer Institute, Aviano (PN),Italy
Keywords: Target therapy, biomarker, pathologist's perspective, Immunohistochemistry, FFPE tissue, molecular analyses, traditional sequencing, next-generation sequencing.
Abstract: The effectiveness of new personalized treatment procedures in oncology is based on the fact that certain tumors exhibit specific molecular features.
More in detail, neoplastic tissues of patients should display a specific biomarker, most often a specific genetic alteration and/or under/overexpression of a definite protein, that could be the target of its respective drug. Immunohistochemical and molecular analyses, which usually include examination of nucleic acids from either tissues or fluids, are common tests to define the status of a tumor.
This review focuses on the pathologist’s role in carefully controlling pre- analytic procedures and standard operating procedures that are a crucial prerequisite to reach reliable and reproducible results. Six paradigmatic applications of targeted therapy, for which pathological diagnosis plays a fundamental role, are summarized. Traditional and next-generation sequencing are also addressed from the pathologist's perspective as well as the importance pathologists have in this shift to more accurate definition of disease risk and prognostication of therapy response in the personalized medicine era.
Export Options
About this article
Cite this article as:
Alessandrini Lara, Perin Tiziana , Kadare Shahin, del Pup Lino, Memeo Lorenzo , Steffan Agostino, Colarossi Lorenzo, Berretta Massimiliano, De Paoli Paolo and Canzonieri Vincenzo*, Cancer Targeted Therapy Strategy: The Pathologist’s Perspectives, Current Cancer Drug Targets 2018; 18 (5) . https://dx.doi.org/10.2174/1568009618666171129145703
DOI https://dx.doi.org/10.2174/1568009618666171129145703 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
Call for Papers in Thematic Issues
Advances in Cancer Biomarkers and Potential Drug Targets: From Diagnosis to Therapy
Cancer biomarkers play a crucial role in the diagnosis, prognosis, and treatment of cancer. They provide valuable information for cancer detection, risk assessment, treatment selection, and monitoring response to therapy. With advancements in molecular biology and high-throughput technologies, there has been an increasing interest in identifying and characterizing cancer biomarkers ...read more
Novel Therapeutic Approaches to Target Drug Resistant Tumors
With the development of disciplines such as chemical biology and molecular biology, the genes or proteins closely related to tumor occurrence and development have gradually become clear. Targeted therapies targeting these genes or proteins provide more effective methods for tumor treatment. Tumor targeted drugs generally only act on specific targets ...read more
ROLE OF IMMUNE AND GENOTOXIC RESPONSE BIOMARKERS IN TUMOR MICROENVIRONMENT IN CANCER DIAGNOSIS AND TREATMENT
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process to explore and investigate the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
Targeting the battlefield between host and tumor: basic research and clinical practice on reshaping tumor immune microenvironment
Immune system protects host against malignant tumors through effector cells and molecules. Cancer development and its response to therapy are regulated by inflammation, which either promotes or suppresses cancer progression. Chronic inflammation facilitates cancer progression and treatment resistance, whereas induction of acute inflammatory reactions often lead to anti-cancer immune responses. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Novel Tri-substituted Thiazoles Bearing Piperazine Ring: Synthesis and Evaluation of their Anticancer Activity
Letters in Drug Design & Discovery Death Receptor Ligands: New Strategies for Combined Treatment with Ionizing Radiation
Current Medicinal Chemistry - Anti-Cancer Agents Nucleic Acid-Based Aptamers: Applications, Development and Clinical Trials
Current Medicinal Chemistry Targeting Neuronal Nicotinic Receptors in Cancer: New Ligands and Potential Side-Effects
Recent Patents on Anti-Cancer Drug Discovery Molecular Pathology of Sarcomas
Reviews on Recent Clinical Trials Recent Patent-Based Perspective on Diagnostic and Therapeutic Interventions in Malignant Mesothelioma: Is Drug Repositioning Knocking on the Door?
Recent Patents on Anti-Cancer Drug Discovery Attenuated Oncolytic Measles Virus Strains as Cancer Therapeutics
Current Pharmaceutical Biotechnology Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response
Current Cancer Drug Targets Pleiotropic Effects of Tocotrienols and Quercetin on Cellular Senescence: Introducing the Perspective of Senolytic Effects of Phytochemicals
Current Drug Targets Phosphoinositide-3-kinases as the Novel Therapeutic Targets for the Inflammatory Diseases: Current and Future Perspectives
Current Drug Targets Immunomodulation and Anti-inflammatory Roles of Polyphenols as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Genistein Potentiates the Anti-cancer Effects of Gemcitabine in Human Osteosarcoma via the Downregulation of Akt and Nuclear Factor-κB Pathway
Anti-Cancer Agents in Medicinal Chemistry Chemical Space of FLT3 Inhibitors as Potential Anti-AML Drugs
Recent Patents on Anti-Cancer Drug Discovery Anti-cancer Immunotoxins, Challenges, and Approaches
Current Pharmaceutical Design Epigenetics of Virus-Induced Tumors: Perspectives for Therapeutic Targeting
Current Pharmaceutical Design HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design 86Y Based PET Radiopharmaceuticals: Radiochemistry and Biological Applications
Medicinal Chemistry Effect of Alpha-1-Acid Glycoprotein Binding on Pharmacokinetics and Pharmacodynamics
Current Drug Metabolism Gene Therapy for Lung Diseases Development in the Vector Biology and Novel Concepts for Gene Therapy Applications
Current Molecular Medicine A Review on Clinical Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT)
Current Vascular Pharmacology